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Introduction
Renewed efforts to control and eliminate malaria are making 
advances using the current generation of tools: long-lasting 
insecticide treated nets, artemisinin combination therapies 
(ACTs) and indoor residual spraying. Despite gains made 
by bednets and spraying, malaria control and elimination 
efforts will continue to rely heavily on chemotherapy and, in 
particular, ACTs.
Currently, the World Health Organization (WHO) en-
dorses four ACT combinations for uncomplicated falciparum 
malaria in non-pregnant adults (Table 1).1 In 2001, WHO 
recommended the use of ACTs due to high efficacy rates and 
potential to reduce the development of resistance.2 By 2009, 
88 countries, including every country in Africa, had officially 
adopted ACTs as first-line agents for uncomplicated malaria.2 
Despite the official guidelines, only 14 countries report distrib-
uting enough ACTs to treat at least 50% of reported malaria 
cases in the public system, and only 5 countries reported 
distributing enough ACTs to treat all cases in 2008.3 Over the 
next 5–10 years, an increasing number of patients, including 
children and pregnant women, will be given ACT therapy.
Combination therapies
Combination therapy, already in use for tuberculosis and HIV, 
is now recommended for malaria treatment to stem the tide 
of resistance and protect the widely available, highly effica-
cious class of drugs, the artemisinins. These combinations 
are based on the unlikely probability of a parasite becoming 
resistant simultaneously to two drugs with unrelated modes 
of action.4 With this in mind, the artemisinins are particularly 
good partner drugs for other antimalarials as they eliminate 
parasites rapidly from the blood and thereby limit the number 
of parasites exposed to the longer acting partner drug.
An example of host genetics
The success of drug therapy is dependent upon many con-
tributing factors, including adherence to prescribed therapy, 
incorrect or suboptimal dosing, general health status and 
interactions with other drugs. Another crucial aspect of the 
lack of effectiveness (often due to low drug levels) and toler-
ability (often due to high drug levels) of chemotherapy is the 
way individuals metabolize the drug. Although the widespread 
use of modern antimalarials began in the 1940s, there was 
limited data about the absorption–distribution–metabolism–
excretion parameters of antimalarials in humans until about 
20 years ago.
The use of primaquine in the 1950s highlights the impor-
tance of pharmacogenetics for antimalarials, as severe reac-
tions to the drug led to the discovery of glucose-6-phosphate 
dehydrogenase (G6PD) deficiency in 1956.5,6 The genetic 
variants among people with G6PD still confound our ability 
to develop effective antimalarials, illustrated by the withdrawal 
of the drug Lapdap® (chlorproguanil/dapsone) in 2008.7 This 
deficiency remains a cause for concern, as primaquine is used 
widely for terminal prophylaxis and to decrease transmission 
intensity by limiting reproduction of the malaria parasites.6
Certainly, scientists have investigated the contribution 
of parasite genetics, in particular relating to drug resistance. 
Several mutations in parasite drug target genes have been 
identified and associated with in vivo resistance to artemis-
inin partner drugs mefloquine, lumefantrine, amodiaquine 
and chlorproguanil.8–16 In addition to parasite genetics, host 
genetics can valuably inform national drug policy decisions 
for first-line antimalarials.
Selection of ACTs
New pharmacology data available for modern antimalarials 
has helped to identify the major metabolic pathways and 
to identify human genetic variations that affect the ability 
to metabolize these agents (Table 2). Beyond the case of 
G6PD, there remain numerous questions about the role that 
pharmacogenetics can play to predict adverse drug reactions 
to antimalarials. Clearly, point-of-care testing for genetic 
variants, such as those of the CYP2C8 gene, is far from a 
reality in the developing world. However, it is possible that 
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pharmacogenetics could help inform 
drug formulary decisions on a regional 
or national scale.
Currently, national malaria control 
programmes select the most appropriate 
drugs for use in the respective country 
based upon costs, in vitro Plasmodium 
falciparum resistance patterns and the 
risk of adverse drug reactions. Very 
little attention has been paid to host 
genetics and their potential to affect 
major formulary decisions by decreasing 
toxicity, increasing efficacy and improv-
ing the time in the therapeutic range 
to combat resistance. This is especially 
important when ministries of health, 
national medicines review authorities 
or national malaria control programmes 
must choose between seemingly equal 
drugs without the aid of comprehen-
sive local pharmacogenetic data (Fig. 1 
and Fig. 2). Importantly, knowledge of 
genetic differences in populations could 
reduce costs by decreasing adverse 
events and increasing efficacy of drugs.
This paper looks at drugs com-
monly used as part of ACTs to treat 
uncomplicated falciparum malaria in 
adults and provides specific examples 
of how genetics may affect drug efficacy 
and toxicity at a population level. It does 
not serve as an exhaustive review of all 
relationships between host genetics and 
antimalarial drugs. Several high-quality 
comprehensive reviews have been done 
elsewhere.17,18Table 3 lists the drugs and 
their potential relationships with vari-
ous genes. This paper discusses ways to 
improve knowledge of genetic data in 
malaria-endemic regions and explores 
the issues that need to be addressed to 
make pharmacogenetic-guided drug 
policy a reality.
Genetics to guide drug 
policy
The case of amodiaquine
The antimalarial amodiaquine is gener-
ally well tolerated, but its use in primar-
ily Caucasian populations in the 1980s 
and 1990s was associated with high 
rates of agranulocytosis (1 in 2100 with 
a case fatality rate of 1 in 31 000) and 
hepatotoxicity (1 in 15 600).19–21 WHO 
removed amodiaquine from the Essen-
tial Medicines List due to the discovery 
of these toxicities, but it was added back 
on the list in the late 1990s as resistance 
to alternative drugs began to appear. 
Recent evidence points to frequent mild 
adverse events caused by amodiaquine. 
A trial in 15 subjects in Africa evaluating 
the pharmacokinetics of amodiaquine 
and the combination of amodiaquine 
and artesunate revealed the common 
adverse events of hepatotoxicity and 
leukopenia after just two doses given 
three weeks apart.22
People with mutant genotypes of 
CYP2C8, CYP1A1 and CYP1B1 have 
been found to have immunogenic 
adverse reactions to amodiaquine.23–28 
Wide variations in the CYP2C8 geno-
type mean that individuals experience 
broad differences in the drug’s efficacy 
and toxicity. Evidence suggests that 
decreased function of the CYP2C8 en-
zyme impairs metabolism of the drug 
and can form a toxic metabolite that 
Table 1. WHO-recommended antimalarial regimens1





Table 2. Human genetic variants important for antimalarial metabolism17
Gene Phenotype Phenotype  
frequency in African 
populations (%)
Phenotype  
frequency in Asian 
populations (%)
Phenotype  






CYP2A6 Poor metabolizer 2 4–12 1 artesunate
CYP2C8 Poor metabolizer 1.5–4 < 0–1 2 amodiaquine
CYP3A5 Poor metabolizer 
with residual CYP3A5 
activity
12–40 60–75 85–95 artemether, 
lumefantrine, 
mefloquine
Poor metabolizer with 
no CYP3A5 activity
10–22 0 0 artemether, 
lumefantrine, 
mefloquine
UGT1A9 Poor metabolizer < 0–1 unknown ≤ 1 DHA
UGT2B7 Poor metabolizer 4–10 6–7 20–25 DHA
Drug transporters
ABCB1 Reduced function 21 69 46 mefloquine
Higher concentration 
of drug substrate
< 1–16 40–45 46–56 mefloquine
DHA, dihydroartemisinin
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Fig. 1. World map showing frequencies of the CYP2C8*2 allele in different populations
x
y < 0.5x
0.5x < y < 2x
2x < y < 4x
y > 4x
x = allele frequency in reference population (US caucasians), y = allele frequency in country with data
Fig. 2. World map showing frequencies of the CYP2C8*3 allele in different populations
x
y < 0.5x
0.5x < y < 2x
2x < y < 4x
y > 4x
x = allele frequency in reference population (US caucasians), y = allele frequency in country with data
Bull World Health Organ 2011;89:838–845 | doi:10.2471/BLT.11.087320 841
Policy & practice
Genetics and malaria drugsMary W Roederer et al.
causes hepatotoxicity and agranulo-
cytosis. Two more common CYP2C8 
variants, CYP2C8*2 and *3, decrease 
the metabolizing ability of CYP2C8 
as evidenced by reduced clearance 
of the anticancer drug paclitaxel and 
arachidonic acid, respectively.29,30 In 
fact, CYP2C8*3 displays no detectable 
metabolizing ability in vitro.30
In a study by Parikh et al., 275 
subjects with malaria from Burkina 
Faso were evaluated for amodiaquine 
metabolism.30 The subjects with the 
CYP2C8*2 genotype (more common 
African variant) experienced more 
abdominal pain than subjects with the 
wild-type (i.e. the normal, non-mutated 
gene) (52% versus 30%; P < 0.01).30 
Other adverse effects did not differ.30 
However, as in many pharmacogenetic 
studies, this study used a rather small 
sample to evaluate rare toxicities and 
did not test for liver function change 
as a marker for hepatotoxicity or phar-
macokinetic changes to test for drug 
concentrations or toxic intermediates. 
Studies in Burkina Faso and Ghana have 
not revealed a relationship between 
drug efficacy and CYP2C8 genotype.30,31
While the percentage of the popu-
lation with an inactivating CYP2C8 
genetic variant is not high in most 
malaria-endemic regions, the overall 
incidence of risk is significant due to the 
burden of disease. For example, Cavaco 
et al. estimated that the CYP2C8*2 and 
CYP2C8*3 genetic variants occur in 
2.1% of the population in Zanzibar, 
United Republic of Tanzania: this trans-
lates into more than 30 000 patients per 
year at risk for severe drug reactions 
to amodiaquine (of a malaria patient 
population of ~1 000 000).32
Ghana example
In Ghana, with a total population of 
more than 25 million, 5 270 108 cases of 
malaria were documented in 2007. The 
majority of these cases were likely treated 
with artesunate plus amodiaquine, the 
first-line treatment of choice on the 
Ghanaian Essential Medicines List.33 
Based on a 1.5% population incidence 
of low-metabolizing CYP2C8, almost 
80 000 (79 052) of these malaria cases 
would have occurred in low metaboliz-
ers (Fig. 1 and Fig. 2). Collecting data on 
adverse drug reactions and their cost is 
the best way to evaluate amodiaquine-
related adverse effects. Without pharma-
covigilance and cost data to model the 
medical costs associated with potential 
adverse drug reactions among these low 
metabolizers, giving this drug combina-
tion to 79 000 low metabolizers each 
year wastes an estimated 0.57 United 
States dollars per treatment course 
(average cost per treatment ranges from 
US$ 0.57–0.88), a total of approximately 
US$ 45 000 a year.34
The known literature on CYP2C8 
allele (gene) frequencies reveals a lack of 
data in malaria-endemic Africa but, in 
those African countries with data, there 
is a higher frequency than in American 
Caucasians (Fig. 1, Fig. 2 and Table 2). 
With the Ghana example showing a loss 
of more than US$ 45 000, the national 
control programme or national medi-
cines review authority could choose an 
alternative from the three first-line anti-
malarial combinations to treat malaria.
Artemisinins
The artemisinins as a group differ in the 
routes they take in the human body to 
convert to the major active metabolite, 
dihydroartemisinin (DHA). Artesunate 
undergoes rapid and extensive conver-
sion via CYP2A6 and, to a lesser extent, 
CYP2B6 and CYP1A1 and CYP1A2.35 
Almost 40 gene variants for CYP2A6 
have been identified; at least 13 of these 
show decreased metabolizing function 
and five show no activity in vivo.36 The 
major antimalarial activity of artesunate 
is performed by DHA.37 People with 
poorly functioning CYP2A6 will have 
higher concentrations of artesunate 
and lower concentrations of DHA. This 
could reduce the drug’s antimalarial 
activity, kill fewer parasites and increase 
the potential for artesunate resistance.
Malaria endemicity is high in many 
areas of sub-Saharan Africa, such as 
Ghana. In contrast, in the Sabah region 
of Malaysia (which has the highest 
endemicity for malaria in this region) 
the burden of disease is considerably 
less than in Ghana. Almost two thirds 
of a Ghanaian population exhibited 
the wild-type genotype of CYP2A6 
with more than 80% allele frequency of 
CYP2A6*1A.38 In contrast, a Malaysian 
population had an observed frequency 
for wild-type genotype of only 8% and 
an allele frequency for CYP2A6*1A 
of approximately 32%.39 With wild-
type responsible for the majority of 
Ghanaian CYP2A6 activity, artesunate 
conversion to DHA and antimalarial 
activity are expected to be normal. In 
the Malaysian population with a low 
wild-type genotype frequency, CYP2A6 
activity is decreased, the conversion to 
DHA decreased, and the antimalarial 
activity of artesunate may be compro-
mised. Studies in other Asian popula-
tions also reveal a high frequency of 
non-wild-type alleles and an especially 
high frequency of the alleles that trans-
late to no CYP2A6 activity (11.5–20.1% 
for Chinese, Japanese, Korean and Thai 
people)38
Resistance to artemisinin-based 
therapies is emerging in Thailand and 
approaches 10% in some areas.40 While 
not established, a potential contributor 
to artemisinin resistance in Thailand 
may be related to CYP2A6 activity (at 
least 14% frequency of the CYP2A6 al-
leles with no activity) and the inability 
to convert artesunate to DHA.41
Table 3. Potential drug–gene relationships for first-line treatments of uncomplicated 
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What next?
Our understanding of the host factors 
contributing to the effectiveness of 
antimalarials is still in its infancy. As 
a community we need to determine 
ways to enhance our ability to study the 
pharmacokinetics and pharmacogenet-
ics of antimalarials to help decrease the 
burden imposed by drug toxicity and 
to help protect their longevity. We can 
do this in three main ways: (i) integrat-
ing pharmacogenetic studies with the 
pharmacokinetic studies of antima-
larials; (ii) increasing the generation of 
human genetic data and (iii) enhancing 
the infrastructure for pharmacogenetic 
research of antimalarial use in endemic 
countries.
Integrating research
Much of the data concerning the phar-
macogenetics of antimalarials is derived 
from small and under-powered studies 
conducted in a retrospective manner. 
In particular, we are lacking significant 
data for some ACT partner drugs, such 
as sulfadoxine-pyrimethamine and 
lumefantrine. A resurgent interest in 
the pharmacology and pharmacokinet-
ics of antimalarials in the malaria drug 
resistance community has spurred the 
development of another potential new 
resource for gathering pharmacogenetic 
data. As part of the Worldwide Antima-
larial Resistance Network, a module has 
been developed to improve the qual-
ity of antimalarial pharmacology data 
generated, to use the new information 
to define drug resistance and to inform 
optimal dosing schedules. The goal is 
to facilitate global cooperation between 
groups active in the antimalarial phar-
macology field (available at: http://www.
wwarn.org). Pharmacology researchers, 
especially pharmacokinetic researchers, 
of antimalarials should obtain informed 
consent from study participants to allow 
use of their samples for collaborative 
pharmacogenetic analysis, either pro-
spectively or in future retrospective 
analyses.
Generating data
Another potential resource for increas-
ing our understanding of the pharma-
cogenetics of antimalarials are national 
control programmes, and the research-
ers and funding agencies associated 
with these programmes. During in vivo 
monitoring and efficacy studies carried 
out by these groups, samples obtained as 
dried blood spots are often collected and 
stored. The amount of DNA collected 
in these samples would not allow for 
assessment of a large number of genetic 
variations but it could allow for targeted 
testing of a small number that are vetted 
in strong pharmacogenetic studies. The 
key would be to encourage these groups 
to obtain consent from patients for 
retrospective human DNA testing. For 
example, considering the four first-line 
treatments, blood spots could provide a 
way to use pharmacogenetics to priori-
tize pharmacotherapy based on genetic 
differences within a defined population 
and to evaluate CYP2C8 genetics. Since 
amodiaquine requires CYP2C8 for 
metabolism to an active agent, national 
control programmes or the national 
medicines review authorities could use 
genotype frequencies in that population 
to determine the priority of a regimen 
containing amodiaquine.
Enhanced infrastructure
Ethnic variability is known for its as-
sociation with antimalarial metabolism, 
but genetic data are missing for much 
of the world’s population. An increas-
ing number of resources and efforts 
has been put into place to help with 
gathering information about the genetic 
make-up of different ethnic groups. In 
malaria-endemic areas, there are no 
pharmacogenetics organizations, such 
as the National Institute of Genomic 
Medicine (INMEGEN) in Mexico, to 
evaluate population genetic differences. 
However, the ideas explored in the white 
paper, Harnessing genomic technologies 
towards improving health in Africa, detail 
the systematic process for improving the 
research infrastructure in Africa.42
There is a strong need for genetic re-
search in Africa. The overarching needs 
are for infrastructure, education and 
training, disease-related research and 
a comprehensive and continued focus 
on ethical, legal and social issues. To 
address these needs the Human Health 
and Heredity in Africa Initiative aims to 
integrate pharmacogenetics in the selec-
tion of national formularies in Africa.
In the meantime, to address the gap 
in knowledge and need for resources to 
evaluate genetic differences in develop-
ing countries, the Pharmacogenetics for 
Every Nation Initiative (PGENI) plans 
to sample 500 people from every ethnic 
group that represents 10% or more 
of the population in 104 developing 
countries.25,43 To avoid any conflicts of 
interest, PGENI declines funding from 
any drug manufacturers. PGENI aims 
to start the development of basic genetic 
knowledge in traditionally underserved 
environments. With the generation of 
medication prioritization algorithms for 
diseases of global importance, PGENI 
produces country-specific, genetically-
enhanced treatment algorithms for 
diseases such as malaria. Using known 
genetic information and the WHO 
recommended treatment for uncompli-
cated malaria, a prioritization algorithm 
includes entry points where pharmaco-
genetics may augment decision-making, 
such as for CYP2C8 and CYP2A6 poly-
morphism frequencies when evaluating 
the use of amodiaquine and artesunate, 
respectively. When considering local 
parasite resistance and drug costs, the 
pharmacogenetically-enhanced, medi-
cal decision-making algorithm becomes 
a practical mechanism for weighing 
the options for formulary inclusion 
or exclusion by national medicines 
review authorities or national control 
programmes.
Countries such as the United King-
dom of Great Britain and Northern 
Ireland and the United States of America 
have made tremendous investments in 
research towards genomic medicine. 
However, in parts of the world where 
national health expenditures are as 
low as US$ 30 a day, the investment in 
genomic research has been extremely 
low.44 Importantly however, some ma-
laria-endemic countries, such as India, 
South Africa and Thailand, have begun 
to invest in large-scale studies of hu-
man genomic variation.45,46 In addition, 
smaller projects, such as the DNA data 
bank in the Gambia and a biobank and 
pharmacogenetics database in Harare, 
Zimbabwe, are emerging and may be 
able to provide valuable data to inform 
national control programmes and medi-
cines review authorities.47,48
Make it practical
While research is necessary to develop 
an objective strategy, individualized 
antimalarial therapy based on genetics 
will not be practical in most endemic 
countries for decades. However, that 
should not prevent the application of 
pharmacogenetic knowledge in public 
policy decisions. Just as regional sam-
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pling of a small number of malaria (or 
HIV or tuberculosis) isolates is used for 
sensitivity predictions for the infecting 
agents, we can use regional data from 
the population as part of the selection of 
therapy. The hope is that international 
cooperation through agencies such as 
PGENI, the Public Population Project 
in Genomics and the Genome-based 
Research and Population Health In-
ternational Network, will help to build 
infrastructure in endemic countries and 
provide the training necessary to sup-
port a sustained skilled human resource. 
Enhancing the research infrastructure 
in developing countries should improve 
the capability for future genetic research 
and support continued efforts to address 
the gaps in knowledge of host genet-
ics. By encouraging collaboration with 
the malaria control programmes and 
parasitologists, as well as with the na-
tional medicines review authorities, the 
stakeholders in genomic research will 
grow substantially and sustainably. Any 
use of human samples will require an 
informed consent that allows future use 
in research, including genetic research. 
As the pharmacogenetic markers with 
significant impact on drug response 
and/or toxicity are vetted, using the 
malaria control programme samples in 
malaria-endemic countries provides a 
good first step to expanding the poten-
tial to impact global drug use through 
improved efficacy and decreased drug 
toxicity. This should help to populate a 
map of pharmacogenetic data to guide 
national formulary decision-making 
by using existing samples, data and 
processes.
Conclusion
To accomplish the considerable goal 
of developing pharmacogenetically-
informed drug policies, there is a need 
for strong collaboration between para-
sitologists studying parasite resistance, 
public health officials from control 
programmes and researchers identify-
ing genetic causes of differences in drug 
toxicity and efficacy. The African Medi-
cines Regulatory Harmonization Initia-
tive will provide a regional regulatory 
process and may allow improvements 
not only at the national but also at the 
regional level.49 These collaborations, in 
conjunction with others investigating 
new drug entities, may help to affect 
the delivery of care to real patients in 
malaria-endemic regions. The work to 
create collaborations and to develop 
systems that allow for sampling large 
populations to establish a map of ge-
netic differences will not be easy, but 
it is certainly worthwhile to include 
pharmacogenetic information when 
considering the data and defining the 
limited number of drugs that will be 
available to a population. ■
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ملخص
هل ميكن لعلم الجينوميات الدوائية أن يحسن من السياسيات الدوائية للمالريا؟
من  الوقاية  يف  باهرًا  نجاحًا  املنسقة  العاملية  اجلهود  حققت  لقد 
إىل  وصل  قد  أنه  يبدو  النجاح  هذا  ولكن  ومكافحتها،  املالريا 
مرحلة الثبات يف كثري من أجزاء العامل. ومع أن هذه املشكلة تعود 
بدرجة  أن سياسات االسرتاتيجيات أمهلت  إال  متعددة،  ألسباب 
كبرية التباين الوراثي بني األشخاص كعامل مؤثر يف اختيار وجرعة 
السمية،  خفض  حماوالت  يشمل  وهذا  للمالريا.  املضادة  األدوية 
وزيادة الفعالية، واحلد من حدوث مقاومة الطفييل لألدوية، ومن 
ثم خفض تكاليف الرعاية الصحية. وقد راجع الباحثون العقبات 
اجلينوميات  بعلم  تسرتشد  سياسات  وتنفيذ  إعداد  أمام  املحتملة 
املنجلية  املالريا  ملعاجلة  واإلقليمي  الوطني  املجالني  عىل  الدوائية 
غري املصحوبة بمضاعفات. كام اهتم الباحثون باملعلومات الراهنة 
العالجية،  األرتيميزين  توليفة  يف  األدوية  مكونات  بعض  حول 
إرشاد  بغرض  املضيف،  الشخص  جلينات  فهمنا  زيادة  وطرق 















La pharmacogénomique peut-elle améliorer la politique des médicaments contre le paludisme?
Les efforts mondiaux coordonnés de prévention et de lutte contre le 
paludisme ont été un véritable tour de force pour la santé publique, 
mais le succès semble avoir atteint un plateau dans de nombreuses 
régions du monde. Bien que ce soit un problème à multiples facettes, 
les stratégies politiques ont largement ignoré les variations génétiques 
chez l’homme en tant que facteur influençant à la fois la sélection et le 
dosage des médicaments antipaludiques. Cela inclut des tentatives pour 
diminuer la toxicité, augmenter l’efficacité et réduire le développement 
de la résistance aux médicaments, réduisant ainsi les coûts des soins de 
santé. Nous passons en revue les obstacles potentiels au développement 
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et à la mise en œuvre des politiques guidées par la pharmacogénétique 
à l’échelle nationale ou régionale pour le traitement du paludisme non 
compliqué à falciparum. Nous examinons également les connaissances 
actuelles sur certains médicaments qui composent les combinaisons 
thérapeutiques à base d’artémisinine et les moyens d’accroître notre 
compréhension de la génétique de l’hôte, dans l’objectif d’orienter les 
décisions politiques de sélection des médicaments.
Резюме
Можно ли с помощью фармакогеномики улучшить политику в области противомалярийных 
препаратов?
Скоординированные глобальные усилия по профилактике 
малярии и борьбе с этой болезнью стали важным достижением 
в сфере общественного здравоохранения. Однако во многих 
странах мира поступательное движение в этой области, по-
видимому, затормозилось. Эта проблема имеет много аспектов, 
однако в политических стратегиях в значительной степени 
игнорировались генетические вариации людей как фактор, 
влияющий на выбор и дозирование противомалярийных 
препаратов. Учет этого фактора включает в себя попытки 
снизить токсичность, повысить эффективность и ограничить 
развитие лекарственной устойчивости, уменьшив тем самым 
расходы на медико-санитарную помощь. Мы исследуем 
потенциальные препятствия на пути разработки и внедрения 
политических мер, опирающихся на фармакогенетику, в 
общенациональном и региональном масштабе для лечения 
несложных случаев заболевания тропической малярией. Мы 
также рассматриваем накопленные в настоящее время знания 
о некоторых многокомпонентных лекарственных препаратах, 
применяемых в рамках артемизин-комбинированной терапии, а 
также способы углубления нашего понимания генетики хозяина 
с целью руководства политическими решениями в области 
подбора лекарств.
Resumen
¿Puede mejorar la farmacogenómica la política de fármacos contra la malaria?
Los esfuerzos coordinados que se están realizando en todo el mundo 
para prevenir y controlar la malaria han sido una auténtica hazaña para 
la salud pública, pero parece que el éxito conseguido se ha estabilizado 
en muchas partes del mundo. Debido a que se trata de un problema 
multifacético, muchas de las estrategias de las políticas han ignorado 
las variaciones genéticas en humanos como un factor que influye 
tanto en la selección como en las dosis de fármacos antimaláricos. Esto 
incluye los intentos de reducir la toxicidad, de aumentar la eficacia y de 
disminuir el desarrollo de resistencia a los fármacos. De esta manera, 
también se reducirían los costes de la asistencia sanitaria. Revisamos los 
posibles obstáculos para el desarrollo e implementación de las políticas 
orientadas a la farmacogenética a nivel nacional o regional para el 
tratamiento de la malaria por Plasmodium falciparum sin complicaciones. 
Con el objetivo de conseguir orientación para las decisiones sobre la 
selección de fármacos, también tenemos en cuenta los conocimientos 
disponibles sobre algunas terapias de combinación de fármacos 
componentes de artemisinina y las maneras de aumentar nuestros 
conocimientos sobre genética del huésped.
References
1. Guidelines for the treatment of malaria. Geneva: World Health 
Organization; 2006. Available from: http://whqlibdoc.who.int/
publications/2006/9241546948_eng_full.pdf [accessed 23 August 2011].
2. Lin JT, Juliano JJ, Wongsrichanalai C. Drug-resistant malaria: the era of 
ACT. Curr Infect Dis Rep 2010;12:165–73. doi:10.1007/s11908-010-0099-y 
PMID:21308525
3. World malaria report 2009. Geneva: World Health 
Organization; 2009. Available from: http://whqlibdoc.who.int/
publications/2009/9789241563901_eng.pdf [accessed 23 August 2011].
4. Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ, White NJ. Antimalarial 
drug resistance, artemisinin-based combination therapy, and the 
contribution of modeling to elucidating policy choices. Am J Trop Med Hyg 
2004;71:179–86. PMID:15331836
5. Carson PE, Flanagan CL, Ickes CE, Alving AS. Enzymatic deficiency in 
primaquine-sensitive erythrocytes. Science 1956;124:484–5. doi:10.1126/
science.124.3220.484-a PMID:13360274
6. Luzzatto L. The rise and fall of the antimalarial Lapdap: a lesson in 
pharmacogenetics. Lancet 2010;376:739–41. doi:10.1016/S0140-
6736(10)60396-0 PMID:20599264
7. Update on GSK’s malaria treatments: Dacart and Lapdap. [media release]. 
29 February 2008. Brentford: GlaxoSmithKline;2008. Available from: http://
www.gsk.com/media/pressreleases/2008/2008_pressrelease_0014.htm. 
[accessed 23 August 2011].
8. Basco LK, Ringwald P. Analysis of the key pfcrt point mutation and in vitro 
and in vivo response to chloroquine in Yaounde, Cameroon. J Infect Dis 
2001;183:1828–31. doi:10.1086/320726 PMID:11372041
9. Berens N, Schwoebel B, Jordan S, Vanisaveth V, Phetsouvanh R, Christophel 
EM et al. Plasmodium falciparum: correlation of in vivo resistance to 
chloroquine and antifolates with genetic polymorphisms in isolates from 
the south of Lao PDR. Trop Med Int Health 2003;8:775–82. doi:10.1046/
j.1365-3156.2003.01099.x PMID:12950663
10. Happi TC, Thomas SM, Gbotosho GO, Falade CO, Akinboye DO, 
Gerena L et al. Point mutations in the pfcrt and pfmdr-1 genes of 
Plasmodium falciparum and clinical response to chloroquine, among 
malaria patients from Nigeria. Ann Trop Med Parasitol 2003;97:439–51. 
doi:10.1179/000349803235002489 PMID:12930607
11. Maguire JD, Susanti AI, Kristin , Sismadi P, Fryauff DJ, Baird JK. The T76 
mutation in the pfcrt gene of Plasmodium falciparum and clinical 
chloroquine resistance phenotypes in Papua, Indonesia. Ann Trop Med 
Parasitol 2001;95:559–72. doi:10.1080/00034980120092516 PMID:11672462
12. Nelson AL, Purfield A, McDaniel P, Uthaimongkol N, Buathong N, Sriwichai 
S et al. pfmdr1 genotyping and in vivo mefloquine resistance on the 
Thai-Myanmar border. Am J Trop Med Hyg 2005;72:586–92. PMID:15891133
13. Ochong EO, van den Broek IV, Keus K, Nzila A. Short report: association 
between chloroquine and amodiaquine resistance and allelic variation 
in the Plasmodium falciparum multiple drug resistance 1 gene and the 
chloroquine resistance transporter gene in isolates from the upper Nile in 
southern Sudan. Am J Trop Med Hyg 2003;69:184–7. PMID:13677373
14. Omar SA, Adagu IS, Warhurst DC. Can pretreatment screening for dhps 
and dhfr point mutations in Plasmodium falciparum infections be used to 
predict sulfadoxine-pyrimethamine treatment failure? Trans R Soc Trop Med 
Hyg 2001;95:315–9. doi:10.1016/S0035-9203(01)90250-0 PMID:11491006
Bull World Health Organ 2011;89:838–845 | doi:10.2471/BLT.11.087320 845
Policy & practice
Genetics and malaria drugsMary W Roederer et al.
15. Pillai DR, Labbe AC, Vanisaveth V, Hongvangthong B, Pomphida S, 
Inkathone S et al. Plasmodium falciparum malaria in Laos: chloroquine 
treatment outcome and predictive value of molecular markers. J Infect Dis 
2001;183:789–95. doi:10.1086/318836 PMID:11181156
16. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L 
et al. Mefloquine resistance in Plasmodium falciparum and increased 
pfmdr1 gene copy number. Lancet 2004;364:438–47. doi:10.1016/S0140-
6736(04)16767-6 PMID:15288742
17. Kerb R, Fux R, Morike K, Kremsner PG, Gil JP, Gleiter CH et al. 
Pharmacogenetics of antimalarial drugs: effect on metabolism 
and transport. Lancet Infect Dis 2009;9:760–74. doi:10.1016/S1473-
3099(09)70320-2 PMID:19926036
18. Mehlotra RK, Henry-Halldin CN, Zimmerman PA. Application 
of pharmacogenomics to malaria: a holistic approach for 
successful chemotherapy. Pharmacogenomics 2009;10:435–49. 
doi:10.2217/14622416.10.3.435 PMID:19290792
19. Hatton CS, Peto TE, Bunch C, Pasvol G, Russell SJ, Singer CR et al. Frequency 
of severe neutropenia associated with amodiaquine prophylaxis against 
malaria. Lancet 1986;327:411–4. doi:10.1016/S0140-6736(86)92371-8 
PMID:2868340
20. Phillips-Howard PA, West LJ. Serious adverse drug reactions to 
pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to 
amodiaquine in Britain. J R Soc Med 1990;83:82–5. PMID:2138674
21. Raymond JM, Dumas F, Baldit C, Couzigou P, Beraud C, Amouretti M. Fatal 
acute hepatitis due to amodiaquine. J Clin Gastroenterol 1989;11:602–3. 
doi:10.1097/00004836-198910000-00034 PMID:2794450
22. Orrell C, Little F, Smith P, Folb P, Taylor W, Olliaro P et al. Pharmacokinetics 
and tolerability of artesunate and amodiaquine alone and in combination 
in healthy volunteers. Eur J Clin Pharmacol 2008;64:683–90. doi:10.1007/
s00228-007-0452-8 PMID:18415093
23. Kerb R, Fux R, Morike K, Kremsner PG, Gil JP, Gleiter CH et al. 
Pharmacogenetics of antimalarial drugs: effect on metabolism 
and transport. Lancet Infect Dis 2009;9:760–74. doi:10.1016/S1473-
3099(09)70320-2 PMID:19926036
24. Li XQ, Bjorkman A, Andersson TB, Ridderstrom M, Masimirembwa CM. 
Amodiaquine clearance and its metabolism to N-desethylamodiaquine is 
mediated by CYP2C8: a new high affinity and turnover enzyme-specific 
probe substrate. J Pharmacol Exp Ther 2002;300:399–407. doi:10.1124/
jpet.300.2.399 PMID:11805197
25. Roederer MW. Cytochrome P450 enzymes and genotype-guided drug 
therapy. Curr Opin Mol Ther 2009;11:632–40. PMID:20072940
26. Clarke JB, Maggs JL, Kitteringham NR, Park BK. Immunogenicity of 
amodiaquine in the rat. Int Arch Allergy Appl Immunol 1990;91:335–42. 
doi:10.1159/000235138 PMID:2210868
27. Harrison AC, Kitteringham NR, Clarke JB, Park BK. The mechanism of 
bioactivation and antigen formation of amodiaquine in the rat. Biochem 
Pharmacol 1992;43:1421–30. doi:10.1016/0006-2952(92)90198-R 
PMID:1567466
28. Jewell H, Maggs JL, Harrison AC, O’Neill PM, Ruscoe JE, Park BK. Role of 
hepatic metabolism in the bioactivation and detoxication of amodiaquine. 
Xenobiotica 1995;25:199–217. doi:10.3109/00498259509061845 
PMID:7618347
29. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI et al. 
Polymorphisms in human CYP2C8 decrease metabolism of the anticancer 
drug paclitaxel and arachidonic acid. Pharmacogenetics 2001;11:597–607. 
doi:10.1097/00008571-200110000-00006 PMID:11668219
30. Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL. 
Amodiaquine metabolism is impaired by common polymorphisms in 
CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther 
2007;82:197–203. doi:10.1038/sj.clpt.6100122 PMID:17361129
31. Adjei GO, Kristensen K, Goka BQ, Hoegberg LC, Alifrangis M, Rodrigues OP 
et al. Effect of concomitant artesunate administration and cytochrome 
P4502C8 polymorphisms on the pharmacokinetics of amodiaquine 
in Ghanaian children with uncomplicated malaria. Antimicrob Agents 
Chemother 2008;52:4400–6. doi:10.1128/AAC.00673-07 PMID:18779360
32. Cavaco I, Strömberg-Nörklit J, Kaneko A, Msellem MI, Dahoma M, Ribeiro 
VL et al. CYP2C8 polymorphism frequencies among malaria patients in 
Zanzibar. Eur J Clin Pharmacol 2005;61:15–8. doi:10.1007/s00228-004-0871-
8 PMID:15785959
33. The health sector in Ghana: facts and figures, 2008. Accra: Ghana Health 
Service; 2008. Available from: http://www.ghanahealthservice.org/includes/
upload/publications/Facts%20and%20Figures%202008.pdf [accessed 23 
August 2011].
34. Drug prices for artesunate/amodiaquine. International Drug Price Indicator 
Guide. Cambridge: Management Sciences for Health; 2009. Available from: 
http://erc.msh.org [accessed 23 August 2011].
35. Li XQ, Björkman A, Andersson TB, Gustafsson LL, Masimirembwa CM. 
Identification of human cytochrome P(450)s that metabolise anti-parasitic 
drugs and predictions of in vivo drug hepatic clearance from in vitro data. 
Eur J Clin Pharmacol 2003;59:429–42. doi:10.1007/s00228-003-0636-9 
PMID:12920490
36. Di YM, Chow VD, Yang LP, Zhou SF. Structure, function, regulation and 
polymorphism of human cytochrome P450 2A6. Curr Drug Metab 
2009;10:754–80. doi:10.2174/138920009789895507 PMID:19702528
37. Ilett KF, Ethell BT, Maggs JL, Davis TM, Batty KT, Burchell B et al. 
Glucuronidation of dihydroartemisinin in vivo and by human liver 
microsomes and expressed UDP-glucuronosyltransferases. Drug Metab 
Dispos 2002;30:1005–12. doi:10.1124/dmd.30.9.1005 PMID:12167566
38. Gyamfi MA, Fujieda M, Kiyotani K, Yamazaki H, Kamataki T. High prevalence 
of cytochrome P450 2A6*1A alleles in a black African population of Ghana. 
Eur J Clin Pharmacol 2005;60:855–7. doi:10.1007/s00228-004-0854-9 
PMID:15660270
39. Yusof W, Gan SH. High prevalence of CYP2A6*4 and CYP2A6*9 alleles 
detected among a Malaysian population. Clin Chim Acta 2009;403:105–9. 
doi:10.1016/j.cca.2009.01.032 PMID:19361454
40. White NJ. Qinghaosu (artemisinin): the price of success. Science 
2008;320:330–4. doi:10.1126/science.1155165 PMID:18420924
41. Noedl H, Socheat D, Satimai W. Artemisinin-resistant malaria in Asia. N Engl J 
Med 2009;361:540–1. doi:10.1056/NEJMc0900231 PMID:19641219
42. Harnessing genomic technologies towards improving health in Africa. 
Bethesda: Human Heredity and Health in Africa Initiative; 2011. Available 
from: http://www.h3africa.org/whitepaper.cfm [accessed 23 August 2011].
43. Marsh S, Van Booven DJ, McLeod HL. Global pharmacogenetics: 
giving the genome to the masses. Pharmacogenomics 2006;7:625–31. 
doi:10.2217/14622416.7.4.625 PMID:16753009
44. Hardy BJ, Seguin B, Goodsaid F, Jimenez-Sanchez G, Singer PA, Daar AS. 
The next steps for genomic medicine: challenges and opportunities for 
the developing world. Nat Rev Genet 2008;9(Suppl 1):S23–7. doi:10.1038/
nrg2444 PMID:18802418
45. Hardy BJ, Seguin B, Singer PA, Mukerji M, Brahmachari SK, Daar AS. From 
diversity to delivery: the case of the Indian Genome Variation initiative. Nat 
Rev Genet 2008;9(Suppl 1):S9–14. doi:10.1038/nrg2440 PMID:18802420
46. Hardy BJ, Seguin B, Ramesar R, Singer PA, Daar AS. South Africa: from 
species cradle to genomic applications. Nat Rev Genet 2008;9(Suppl 
1):S19–23. doi:10.1038/nrg2441 PMID:18802417
47. Sirugo G, Schim van der Loeff M, Sam O, Nyan O, Pinder M, Hill AV et al. A 
national DNA bank in The Gambia, West Africa, and genomic research in 
developing countries. Nat Genet 2004;36:785–6. doi:10.1038/ng0804-785 
PMID:15284842
48. Matimba A, Oluka MN, Ebeshi BU, Sayi J, Bolaji OO, Guantai AN et al. 
Establishment of a biobank and pharmacogenetics database of African 
populations. Eur J Hum Genet 2008;16:780–3. doi:10.1038/ejhg.2008.49 
PMID:18382479
49. Ndomondo-Sigonda M, Ambali A. The african medicines regulatory 
harmonization initiative: rationale and benefits. Clin Pharmacol Ther 
2011;89:176–8. doi:10.1038/clpt.2010.299 PMID:21252936
